| 000 | 01844 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518034119.0 | ||
| 264 | 0 | _c20200505 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a1573-675X | ||
| 024 | 7 |
_a10.1007/s10495-019-01543-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiles, Mark A | |
| 245 | 0 | 0 |
_aProteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent. _h[electronic resource] |
| 260 |
_bApoptosis : an international journal on programmed cell death _c06 2019 |
||
| 300 |
_a404-413 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBortezomib _xpharmacology |
| 650 | 0 | 4 |
_aCaspase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aCaspases _xmetabolism |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDNA Damage |
| 650 | 0 | 4 |
_aDeoxyribonucleases _xdeficiency |
| 650 | 0 | 4 |
_aDepsipeptides _xpharmacology |
| 650 | 0 | 4 |
_aHistone Deacetylase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoxanthine Phosphoribosyltransferase _xgenetics |
| 650 | 0 | 4 |
_aMitochondria _xdrug effects |
| 650 | 0 | 4 | _aMutagenesis |
| 650 | 0 | 4 |
_aMutation _xdrug effects |
| 650 | 0 | 4 |
_aPoly-ADP-Ribose Binding Proteins _xdeficiency |
| 650 | 0 | 4 |
_aProteasome Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aVorinostat _xpharmacology |
| 700 | 1 | _aHarris, Michael A | |
| 700 | 1 | _aHawkins, Christine J | |
| 773 | 0 |
_tApoptosis : an international journal on programmed cell death _gvol. 24 _gno. 5-6 _gp. 404-413 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10495-019-01543-x _zAvailable from publisher's website |
| 999 |
_c29600918 _d29600918 |
||